Omalizumab
Description
Omalizumab is used for the management of moderate to severe persistent allergic asthma in patients whose symptoms are inadequately controlled with inhaled corticosteroids. It is also used for the treatment of chronic idiopathic urticaria (hives) without a known cause in patients who have not responded successfully with antihistamine treatment. This medicine is not indicated to treat other forms of urticaria or relief of acute bronchospasm or status asthmaticus.
QUICK LINKS:
Side effects
Major & minor side effects for Omalizumab
- Redness, blistering, peeling, or loosening of skin
- Cough
- Headache
- Dizziness
- Difficulty with swallowing
- Chest tightness
- Unsual tiredness or weakness
- Pain in the joints, arms, or legs
Uses of Omalizumab
What is it prescribed for?
- Asthma - Maintenance
- Chronic idiopathic urticaria (CIU)
Read More
Concerns
Commonly asked questions
- Onset of actionThe amount of time required for this medicine to show its action is not clinically established.
- Duration of effectThe amount of time for which this medicine remains active in the body is not clinically established.
- Safe with alcohol?Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
- Is it habit forming?No habit-forming tendencies were reported.
- Usage in pregnancy?This medicine is not recommended for use in pregnant women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine.
- Usage while breast-feeding?This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine. Your doctor may advise you to discontinue the drug or to discontinue breastfeeding based on your clinical condition.
Allergy
This medicine is not recommended for use in patients with a known allergy to Omalizumab or any other inactive ingredients present along with it.
Warnings for special population
Pregnancy
This medicine is not recommended for use in pregnant women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine.
Breast-feeding
This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine. Your doctor may advise you to discontinue the drug or to discontinue breastfeeding based on your clinical condition.
General warnings
Use in children
The safety and efficacy of Omalizumab for the management of allergic asthma is not clinically established in children below 6 years of age. In chronic idiopathic urticaria, safety and efficacy of Omalizumab is not clinically established in children below 12 years of age.
Anaphylaxis
This medicine may cause severe anaphylactic reactions presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue, etc. in some patients. Appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be required in some cases based on the clinical condition.
Parasitic infections
This medicine should be used with extreme caution in patients at high risk of geohelminth infection due to the risk of worsening of the patient's condition. Appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be required in some cases based on the clinical condition.
Missed Dose
Since this medicine is usually administered by a qualified healthcare professional in the clinical/hospital setting, the likelihood of a missed dose is very low.
Overdose
Since this medicine is administered in the hospital setting by a qualified healthcare professional, the likelihood of an overdose is very less. However, emergency medical treatment will be initiated by the doctor if an overdose is suspected.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol
Description
Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Instructions
Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Interaction with Medicine
Omacetaxine
Disease interactions
Malignancies
This medicine should be used with extreme caution in patients with a history or at risk of malignancies due to the risk of worsening of the patient's condition. Close monitoring of the clinical condition, appropriate dose adjustments, or replacement with a suitable alternative may be required in some cases based on the clinical condition.
Food interactions
Information not available.
Lab interactions
Information not available.
This medicine is usually administered in the clinical/hospital setting under the supervision of a qualified healthcare professional. Follow all the instructions given by your doctor. Inform the doctor if you have a known allergy to this medicine. Report all your current medicines as well as your medical conditions to the doctor before receiving this medicine.
Miscelleneous
How it works
This medicine inhibits the actions of certain chemical substances that trigger allergic symptoms.
Legal Status
Classification
Category
Monoclonal antibodies, Other immunosuppressants, Anti-asthmatics
Schedule
Schedule H
DailyMed - Xolair- omalizumab injection, solution Xolair PFS- omalizumab injection, solution [Internet]. Dailymed.nlm.nih.gov. 2018 [cited 28 December 2018]. Available from:
Omalizumab - DrugBank [Internet]. Drugbank.ca. 2018 [cited 28 December 2018]. Available from:
Xolair 150mg Solution for Injection - Summary of Product Characteristics (SmPC) - (eMC) [Internet]. Medicines.org.uk. 2018 [cited 28 December 2018]. Available from:
[Internet]. Accessdata.fda.gov. 2018 [cited 28 December 2018]. Available from:
Allergic Asthma and CIU Treatment | Xolair® (Omalizumab) [Internet]. Xolair.com. 2019 [cited 5 March 2019]. Available from:
Bolstran Injection [Internet]. CiplaMed. 2019 [cited 5 March 2019]. Available from:
Information on this page was last updated on 5 Mar 2019
Disclaimer
We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.